Gerry (Gerald) Klein, MD

Of the approximately 4,500  FDA-approved drugs, the vast majority are generic, over 80%. Once a drug goes generic, its price drops as multiple manufacturers begin producing it,  resulting in little financial incentive for further research. Despite their affordability, these generic drugs possess enormous potential, yet our system often overlooks them because they are no longer considered profitable. At Every Cure, we believe this gap in research and innovation is unacceptable. We are dedicated to unlocking the potential of these generic drugs to treat diseases that currently lack effective therapies. #pharma #raredisease #drugdevelopment #drugdiscovery

76

7 Comments

10 Largest #MedTech companies - 2024 Forecast Annual volume of primary TJAs will grow 70% to 2,257,326 Higher growth in demand for THAs compared to TKAs (1,219,852 THAs vs. 1,037,474 TKAs by 2050). Active orthopedic surgeons is projected to decrease 14% by 2050 In 2017, the average primary TJA caseload per active orthopedic surgeon was 65.2 procedures while the projected TJA-ASRs for 2050 is 139.4. The number of TJAs performed per surgeon will double by 2050 to meet the projected demand. Increasing the number of orthopedic surgeons by 10% every five years could ensure the caseload per surgeon remains similar to the 2010 to 2017 numbers Further areas of growth moving forward will be artificial intelligence (AI) and data interoperability, which form the basis for effective digital health strategies, supporting the shift toward value-based care – the best, cost-effective health outcomes for patients. These indicators for increased orthopedic surgeries, growing ASCs, and embracing digital health will have machine tool builders seeing more demand for high-efficiency equipment as job shops and contract manufacturers produce more implants, bone screws, plates, and the surgical tools required to complete each procedure. Automation will continue its growth in manufacturing as lack of skilled workers remains a challenge but the reshoring of medtech manufacturing will demand more efficient operations.

18

🔬 Advancing Precision Oncology in Metastatic RCC New findings highlight the potential of longitudinal ctDNA monitoring as a predictive biomarker for treatment response and progression-free survival in metastatic renal cell carcinoma (RCC). This study demonstrates high concordance between ctDNA dynamics and clinical outcomes, paving the way for more personalized approaches to therapy and surveillance. Discover how these insights could impact the future of RCC management. 📖 Read the full study here: https://lnkd.in/ejQhtz6H #RenalCellCarcinoma #ctDNA #PrecisionMedicine #CancerResearch #OncologyInnovation

9

1 Comment

The current #CancerCare pathway has its challenges.   🩸 MRD testing, through ctDNA liquid biopsy, enables faster, more accurate detection of cancer relapse, allowing for:   •       Fewer unnecessary treatments and side effects •       Improved health outcomes and quality of life •       Reduced psychological stress for patients   By gathering precise insights into the Minimal Residual Disease (MRD), we can guide every decision to improve outcomes and quality of life.   GUIDE.MRD is launching a public consultation to gather multi-stakeholder perspectives and ensure this approach meets real-world needs.   Only by working together can we shape a future of #cancercare that integrates ctDNA into guidelines and clinical practice.    We encourage you to share your insights and collaborate on the public consultation ⏩ https://bit.ly/4htCR4T    #liquidbiopsy #precisiononcology _____   @Universitätsklinikum Hamburg Eppendorf, @Aarhus University, @UMCG, @Centre Hospitalier Universitaire de Nice (CHU de Nice), @CNIO - Spanish National Cancer Research Centre, @LungenClinic Grosshansdorf GmbH, @Karolinska Institutet, @Illumina, @Horizon Discovery, @LGC Clinical Diagnostics, @The Synergist.org, @Digestive Cancers Europe, @Amgen, @Bristol Myers Squibb, Roche, @Innovation Acta S.r.l., @AstraZeneca, @Medizinische Universität Graz, @Centre for Innovation in Medicine, @Aarhus Universitetshospital, @Region Stockholm, @Lung Cancer Europe, @AbbVie _____   This work is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112066. The JU receives support from the European Union’s Horizon Europe research and innovation program and EFPIA (including Vaccines Europe), MedTech Europe and LGC Clinical Diagnostics Inc. Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.  

15

In 2024, 5 emerging BTK inhibitors are undergoing late-phase clinical investigation for #multiplesclerosis. Most clinicians are likely unaware of the clinical data regarding their use in MS. Dive into the data and earn free #CME here: https://bit.ly/4gViIVp #MedEd #FOAMed

2

A Comprehensive Overview of the Saudi and Arab Pharmaceutical Market: The Saudi and Arab pharmaceutical markets are transforming rapidly! Saudi Arabia alone surged from $8.6 billion in 2019 to $11.3 billion in 2023, leading regional growth driven by Vision 2030 initiatives, healthcare innovation, and robust investment. From enhanced research capabilities to manufacturing expansion, the sector aligns with national goals for economic diversification and global competitiveness, fueling unparalleled opportunities across the Arab world! Read more in this detailed overview from Makkah Newspaper: https://lnkd.in/dT4dDdXq

33

2 Comments

Offering in-office biologic therapies 🧪 to ankylosing spondylitis patients is an innovative approach that can significantly ✅ enhance patient care.

1

GHC65: #H5N1 update; #vitaminD enhances immunity; #genetherapy for #hemophilia B; #monoclonal protects against #malaria; #cryptococcus review; #vaccine #confidence in 23 #countries: see all here:

11

This content is for US audiences only.   Yesterday, the FDA’s Oncologic Drugs Advisory Committee (ODAC) acknowledged that our IO treatment met the primary endpoint of event-free survival (EFS) in the treatment of resectable non-small cell lung cancer (NSCLC) based on the AEGEAN Phase III trial results with an overall tolerable safety profile.   Those potential benefits cannot be understated, as the majority of this patient population faces a disease recurrence even after surgery and chemo.   This announcement is welcome news to patients thanks to its flexibility before or after surgery and more time to live without progression or recurrence. Our patients are relying on us to deliver new powerful therapies that will allow them to live longer and better – and we won’t let them down. We look forward to our continued work with the FDA and the potential to bring safe, powerful treatments to even more patients facing a cancer diagnosis. Read more: https://bit.ly/46h4YiN   #USOnly #AstraZenecaUS

160

3 Comments

And the McCullough Foundation forget to mention that COVID infected individuals have a 7 fold risk of myocarditis compared to vaccinated individuals. And be aware of the numerous limitations of the study which raise question about the study itself with the inappropriate control group… Therefore a cautious interpretation of the results is needed. Recent studies have indicated that the risk of myocarditis and pericarditis is highest after the second dose of mRNA vaccines, but not to the extent of COVID infection.Therefore, investigating the interaction effects between COVID-19 and vaccine type specifically after the second dose would have been particularly useful. Nevertheless, the findings of this study offer valuable insights. Future research will address this gap by examining the interaction effects following the second and booster doses. When defining acute heart disease as a potential AE of vaccination, we excluded individuals diagnosed with acute heart disease before their vaccination date.

6

Biomarkers can impact colorectal cancer treatment options. By testing for biomarkers, your medical team can personalize your treatment based on the unique mutations in your tumor, choosing the most effective treatments and helping you avoid unnecessary treatment or side effects. These test results can also connect you with clinical trials testing targeted therapies.    Today, on World mCRC Day, we join our international advocacy partners to raise awareness of metastatic CRC (mCRC) and biomarkers, including the impact biomarkers have on mCRC treatment.     Please visit  https://lnkd.in/eGcbN9xb learn more. #worldmCRCDay #colorectalcancer #coloncancer #bowelcancer 

5

NEO | AML Express supports better outcomes for acute myeloid leukemia patients with rapid, detailed genetic insights to guide treatment decisions. This panel provides a comprehensive NGS-based assessment with actionable diagnostic and prognostic information. Crucial biomarker data gives you the insights to make informed, personalized treatment decisions to ensure that your patients receive the most current and effective treatments. Order today: https://lnkd.in/gvBh4h7x #AML #AcuteMyeloidLeukemia #NGS #CancerTesting #Oncology

42

💊 #Wegovy Advances in #MASH Treatment but Faces Limits as a Long-Term Solution GLP-1s strike again... ❗ Wegovy’s results offer meaningful progress in addressing MASH, a complex and increasingly prevalent #liverdisease that currently lacks effective long-term treatments. However, while #GLP-1 receptor agonists like semaglutide show promise, they’re unlikely to revolutionize MASH management on their own, as evidenced by modest fibrosis improvement and the need for polypharmacy to address multifaceted disease pathways. This outcome aligns with broader trends in the field, where combination #therapies appear crucial to tackling the advanced stages of MASH. As Wegovy and similar drugs progress, their ultimate value may lie in complementary roles alongside other #treatments, reshaping MASH care without single-handedly transforming it.

23

1 Comment

American Society of Clinical Oncology (ASCO) GU25 abstract titles are now available Society of Urologic Oncology, Inc https://lnkd.in/eueQJbP5 #ASCO #ASTRO #Cancer #OncoDaily #Oncology #Medicine #Health

21

🗞 Breaking news 🤩 Genezen acquire uniQure's commercial GT manufacturing ops in Lexington!! This strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. Check out full article below👇 #CDMO #Genezen #GeneTherapy

18